Announcements
- Pharming Group announces the placement of €100 million convertible bonds due 2029
- Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
- Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
- Pharming Group announces the 2024 Annual General Meeting of Shareholders
- Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
- Pharming Group to participate in April investor conferences
- Pharming Group reports fourth quarter and full year 2023 financial results
- Pharming Group to report fourth quarter and full year 2023 financial results on March 14
- Pharming Group to participate in February investor conferences
- Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.12 |
---|---|
High | 1.12 |
Low | 1.12 |
Bid | 1.07 |
Offer | 1.07 |
Previous close | 1.12 |
Average volume | -- |
---|---|
Shares outstanding | 671.07m |
Free float | 655.38m |
P/E (TTM) | -- |
Market cap | 584.02m EUR |
EPS (TTM) | -0.0163 EUR |
Data delayed at least 15 minutes, as of Apr 11 2023.
More ▼